Skadden, Arps, Slate, Meagher & Flom has advised Shanghai-based biopharmaceutical company JHBP (CY) Holdings, a holding company for Genor Biopharma,  on its HK $2.87 billion ($371 million) IPO in Hong Kong, with Kirkland & Ellis representing the joint sponsors and the underwriters.

Founded in 2007, Genor is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs The public offering was oversubscribed 1,247 times, making it one of the most sought-after biotech IPOs in Hong Kong this year.

The offering is part of a recent flurry of IPOs and secondary listings worth at least $4.5 billion currently being launched in Hong Kong, with Reuters reporting that 2020 is on track to be the second-busiest year for equity capital markets in the city. Recently, Chinese companies Yum China Holdings, Zai Lab and ZTO Express undertook successful secondary listings on HKEX while Ming Yuan Cloud Group went public in Hong Kong.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Skadden, Jia Yuan, Freshies, KWM act on Midea’s $3.5 bln HK share offering

by Asian Legal Business《亚洲法律杂志》 |

Skadden, Arps, Slate, Meagher & Flom and Jia Yuan Law Offices are advising Chinese home appliance maker Midea Group on its HK$26.97 billion ($3.46 billion) share offering in Hong Kong, the city's largest listing in more than three years.

Deals

Skadden, STB advise on Timee’s $435mln Japan IPO

by Nimitt Dixit |

U.S. law firm Skadden, Arps, Slate, Meagher & Flom has guided Timee, Inc, a Japanese on-demand job platform, on its $435 million initial public offering and listing on the Tokyo Stock Exchange. Simpson Thacher & Bartlett advised the international managers on the deal.

Deals

Skadden, Latham act on $1.1 bln Japan outbound pharma deal

by Asian Legal Business《亚洲法律杂志》 |

Skadden, Arps, Slate, Meagher & Flom has advised Japan's Otsuka Pharmaceutical on its $1.1 billion agreement to acquire Boston-based Jnana Therapeutics, which was represented by Latham & Watkins.